Slides
Page 1
Private & Confidential Investor Presentation November 04, 2026
Page 2
2 Private & Confidential Disclaimer This presentation has been prepared by Krishna Institute of Medical Sciences Limited (the “Company”) solely for informational purposes. It should not be construed as an offer, solicitation, or recommendation to purchase or subscribe for any securities of the Company or its affiliates. The information contained herein has been compiled from sources believed to be reliable; however, the Company makes no representation or warranty, express or implied, as to the accuracy, completeness, or correctness of such information. Recipients are advised not to place undue reliance on this presentation and are encouraged to conduct their own independent analysis and consult with professional advisors before making any investment or business decisions. This presentation may contain forward-looking statements that involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied. These statements reflect the current expectations and beliefs of the Company’s management as of the date hereof and are subject to change without notice. The Company undertakes no obligation to update or revise any forward-looking statements in light of new information or future events. Neither the Company nor any of its directors, officers, employees, affiliates, or advisors accepts any liability whatsoever for any loss, cost, or damage arising directly or indirectly from the use of this presentation or its contents. This presentation has not been approved and will not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange(s) in India. This material does not purport to be comprehensive or to contain all the information a potential investor may require. Any investment decision should be based on a thorough review of publicly available information and independent professional advice suited to the specific circumstances of each investor. By accessing or attending this presentation, you acknowledge that you understand and agree to the terms of this disclaimer. Any disputes arising from or relating to this presentation shall be governed by and construed in accordance with the laws of India, and the courts in Hyderabad, Telangana, India shall have exclusive jurisdiction.
Page 3
3 Private & Confidential Most Preferred Healthcare Provider PATIENTS DOCTORS EMPLOYEES INVESTORS Affordable Quality Care Best-in-Class Facilities Patient Centric Systems & Processes Clinical Outcome Driven Excellence Latest Medical Technology Strong Academics & Research Oriented Enriching Atmosphere Collaborative Culture Growth Driven Career Approach Transparent Governance Strong Operational Performance Consistent Growth VISION: To be the most preferred healthcare services brand by providing affordable care and best clinical outcomes to patients. And to be the best place to work for doctors and employees. OUR MISSION: Provide affordable quality care to our patients with patient-centric systems and processes. Enable clinical outcome-driven excellence by engaging modern medical technology. Provide a strong impetus for doctors to pursue academics and medical research. Driven by a Vision
Page 4
4 Private & Confidential Brain • Neurology • Neurosurgery • Psychiatry • Neuro Rehabilitation Heart • Cardiology • Cardiac Surgery • Vascular Surgery • Heart Transplant • Cardio Rehabilitation Lung • Pulmonology • Interventional Pulmonology • Thoracic surgery • Lung Transplant ENT • Ear • Nose • Throat • Head and Neck Surgery Eyes • Ophthalmology Gastro Intestinal Tract • Medical Gastroenterology • Surgical Gastroenterology • Hepatobiliary Pancreatic Surgery • Liver Transplant • Bariatric Surgery Genito Urinary Tract • Nephrology • Urology • Andrology • Renal Transplant • Gynecology • Urogynecology • IVF and ART • Fetal Medicine • Obstetrics Oncology • Medical Surgical and Radiation • BMT and Hematology Bones and Spine • Orthopedics • Arthroscopic Surgery • Spine Surgery • Ortho Rehabilitation Skin • Dermatology • Cosmetology • Plastic and Reconstructive Surgery Orthodontics • Maxillo Facial Surgery Anaesthesia • OT Anaesthesia • Day care Anaesthesia • Pain Medicine General Specialities • Internal Medicine • General Surgery • Diabetology & Endocrinology Pediatrics • Pediatrics & Pediatric Sub Specialities • Neonatology Radiology • Imaging • Interventional Radiology Lab Services • Pathology • Microbiology • Biochemistry • Molecular Biology • Clinical Hematology Critical Care Services • ICU • CTICU • SICU • NICU • PICU • Neuro ICU • ECMO ICU • Post Transplant ICU Hospital Infection Control • Clinical Infectious Diseases Multi Specialty Care
Page 5
5 Private & Confidential A legend in CT Surgery, Dr. Bhaskara Rao Bollineni {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio-Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. Well known in the medical fraternity for his passion towards his profession, Dr. Bhaskara Rao Bollineni started his entrepreneurial journey at “Mahavir Cardio Vascular Centre” in Hyderabad with 50 beds and performed heart surgeries at an unimaginable low cost of just Rs. 45,000 only. Dr. Bhaskara Rao Bollineni never turned away any patient from the hospital for want of money. The brand “Krishna Institute of Medical Sciences”, under Dr. Bhaskara Rao Bollineni aegis began its journey in 2004 with a 300 bed hospital on par with the then established hospitals of Hyderabad in professional excellence, the state of art technology and infrastructure facilities. Today KIMS is spread across Telangana, Andhra Pradesh, Maharashtra, Karnataka and Keralam. Dr. Bhaskara Rao Bollineni was instrumental in formulating Rajiv Gandhi Aarogyasri scheme, first time launched in Andhra Pradesh in 2007 for providing health care to the poorest of the poor. This prestigious scheme has won him accolades from all quarters of the country and the world. He was the chief architect of Aarogyashri scheme for both creating it and implementing it successfully. This well formulated scheme has become so popular that the other States in India have emulated it time and again. Dr. Bhaskara Rao Bollineni - Visionary Behind KIMS Chairman & Managing Director
Page 6
6 Private & Confidential Dr. Abhinay Bollineni Executive Director & CEO Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. He was appointed as the CEO in 2019. Dr. Abhinay Bollineni completed MBBS from the Deccan Medical College, Hyderabad, in 2010. He was the lone qualified medical practitioner from India to be selected by the office of Hillary Clinton in 2011, where he participated in the ‘International Visitor Leadership Program on Oncology: Research, Prevention and Treatment’ held by the US Department of State He was named in Business World’s “BW 40 Under 40” list in 2019. Under his stewardship, KIMS Hospitals got successfully listed on the Stock Exchanges in India in 2021. Dr. Abhinay Bollineni is passionate about using technology to enhance patient experience and clinical care. Towards this, he has spearheaded vital initiatives such as Financial counseling tool which uses AI to help patients with surgery costings among many others
Page 7
7 Private & Confidential Board of Directors Dr. Bhaskara Rao Bollineni Chairman & Managing Director Dr. Abhinay Bollineni Executive Director & CEO Mrs. Anitha Dandamudi Whole-time Director Mr. Saumen Chakraborty Independent Director, Chairman (Audit Committee) Mr. Ratna Kishore Kaza Independent Director Chairman (Nomination & Remuneration Committee) Mr. Venkata Ramudu Jasthi Independent Director Mr. Adwik Bollineni Executive Director Mrs. Y . Prameela Rani Independent Director Chairman (Stakeholders’ Relationship Committee) Mr. Suresh Natwarlal Patel Independent Director
Page 8
8 Private & Confidential Shareholding Pattern - As on 30th September, 2026 Promoters, 32.5% DII, 33.8% Retail Pre IPO, 6.3% Retail & Others, 9.8% FII, 17.6% Share Holder Share Holding % SBI MF 4.9% Kotak MF 4.8% AXIS MF 4.8% HDFC MF 4.0% Invesco MF 3.6% Nomura 2.7% Vanguard 2.4% Amansa Holdings Private Limited 2.2% Nippon MF 2.0% LILAC Investments Limited 1.9% Top Institutional Share Holders
Page 9
9 Private & Confidential Modern Medical Technology Other Key Equipments • O-Arm Scanner • Spy Glass • Fibroscan • Novalis Tx Linear Accelerator • Cuvis Ortho Robo • EBUS • STEALTH STATION S8 • IMPELLA • EVIS X1 Endoscopy System • 4-Arm HD da Vinci Robotic Surgical System 4-Arm HD da Vinci Robotic Surgical System Facilitates complex surgeries that are virtually scarless. New Robots procured for Secunderabad, Kondapur, Nagpur & Kannur. MrGFUS Focussed Ultrasound Revolutionary Knifeless Brain procedure for treating tremors. Proven to reduce Tremors severity and improve quality of life for Parkinson’s & Essential Tremors Patients. Mako Robotic for Knee Replacement Produces minimal blood loss and a smaller scar. Helps preserve healthy bone and soft tissue. Results in less post-operative pain than manual techniques. ESWL Dornier It offers powerful imaging, maximized energy, and enhanced efficiency. It allows for better diagnosis, better treatment, and better patient follow-up at no additional radiation risk. Tulsa-Pro System A non- invasive procedure that uses real-time MRI guidance to precisely deliver thermal ablation for treating BPH (Benign Prostatic Hyperplasia) and prostate cancer, preserving surrounding healthy tissue. Gamma Knife A non-invasive radiosurgery procedure that uses focused beams of gamma radiation with real-time imaging to precisely treat brain tumors, vascular malformations, and functional brain disorders - without a surgical incision.
Page 10
10 Private & Confidential Many Firsts... • First in Asia to do Trans catheter Tricuspid Valve replacement procedure done in 2018 • Largest Joint replacement program in South Asia. • One of the largest neuroscience programs for epilepsy among private hospitals in the country • Largest ECMO program (18 machines) in the country. • First hospital in Hyderabad to use an ECMO machine in 2013. • First hospital in Hyderabad to do a Neonatal ECMO • First in India to do TOF repair using CorMatrix patch for pulmonary valve reconstruction in 2017 • First in the country to do Robotic spleen preserving distal pancreatectomy • India’s first COVID Double Lung transplant done in 2020 • India’s first Breathing Lung transplant done in 2021 • First hospital in South India to introduce Da Vinci Robotic System • The first hospital in Andhra Pradesh and Telangana to have been Green OT certified in 2016 • First hospital in India to perform Arch Repair in Neonates and infants without TCA • First Hospital in South India to do Total Skin Electron Beam Radiation therapy in 2018 • Number 1 player in Organ transplantation speciality (Heart, Lung, Liver and Kidney) • Number 1 in Nephrology treatments in Andhra Pradesh • Number 1 in Neurosurgery & Poly trauma treatments in Andhra Pradesh • Number 1 in Cardio related surgeries and treatments programs in Andhra Pradesh • Number 1 in Urology (Genito-Urinary) surgeries performed in Andhra Pradesh
Page 11
11 Private & Confidential Key Accomplishments Neurology India Journal 2016 Neurology Department at KIMS Secunderabad ranked 3rd in India National Quality Excellence Awards 2019 KIMS Sec. Best Super-Specialty Hospital in Telangana Times Health Survey Times of India 2021 Ranked No.1 in Hyderabad for Cardiology, Neurosciences, Nephrology, Emergency & Trauma 2020 Only Hospital in Telangana to get NABH Accredition for Emergency Department Pharmacie De Qualite (PDQ) Certification Overall PDQ Evaluation Performance Score - 98% Grading - PLATINUM Ranked No. 1 Hospital by Times of India, Hyderabad ‘Patient Friendly Hospital’ AHPI Health Care Excellence Award (2017) NABH Digital Standards Accreditation received for Kondapur INTERNATIONAL ACCREDITATION QUALITY & PATIENT SAFETY American Accreditation Commission International (AACI) Accredited 2nd Best Hospital in Hyderabad (2021 & 2022) ‘Best Hospital to Work For’ AHPI Global Conclave Award (2019) National Quality Excellence Awards 2019 for Best Super Specialty Hospital in Telangana
Page 12
12 Private & Confidential Consistent Performer over 2 decades (Rupees in Millions) 1) *EBITDA before IND AS and other income. 2) **FY22 EBITDA includes share of profit from JV (Sunshine). *EBITDA 2005 2010 2015 2020 2022** 2023 2024 42 317 773 5,766 6,200 2,412 5,217 CAGR: 28.1% 2025 7,590 2026 7,584 Total Revenue 2005 No. of Hospitals: 1 2010 No. of Hospitals: 3 2015 No. of Hospitals: 5 2020 No. of Hospitals: 9 2022 No. of Hospitals: 12 2023 No. of Hospitals: 12 263 1,311 4,280 11,287 16,711 22,235 2024 No. of Hospitals: 12 25,143 CAGR: 26.9% 2025 No. of Hospitals: 18 30,670 2026 No. of Hospitals: 26 39,308
Page 13
13 Private & Confidential KIMS Journey: From Regional Leader to National Healthcare Roadmap Overall Bed Capacity of 10,000+ Beds 3,447 3,109 1,309 1,068 800 300Total Kurnool - 200 Gachibowli - 223 Nellore - 2502000 Andhra Pradesh Telangana Maharashtra Keralam Karnataka Tamil NaduYear Rajahmundry - 1952001 Secunderabad - 10002004 Srikakulam - 3002011 Kondapur - 2202014 Ongole - 3502017 Vizag - 4342018 Anantapur - 2502019 Begumpet - 369 Nagpur - 3342022 Vizag II - 335 Asian Transcare - 60 Nashik - 325 Kannur - 1892024 Sangli (O&M) - 350Guntur Shikara (O&M) - 2002025 Thane - 300 Kollam - 320 Thrissur (O&M) - 351 Mahadevapura - 450 Guntur Chakra (O&M) - 100 Kondapur II - 787 Arete (O&M) - 250 Palakkad - 208 Electronic City - 350 Planned Chennai - 300 Kompally (O&M) - 2002026 Rajahmundry II - 350 Anantapur II - 250 Ongole - 50 Kakinada - 183
Page 14
14 Private & Confidential KIMS Journey: Strategic Levers for Future Growth Consistent Growth over 2 decades Achieved 26%+ CAGR in Revenue and 28%+ CAGR in EBITDA, reflecting sustained operational excellence and strategic expansion. Delivering high-quality care through affordable healthcare models, advanced transplant programs, and cutting-edge medical technology. Recent Acquisition: Successfully turned around EBITDA from single-digit % to double-digit % post-integration, reflecting operational and financial improvement. Strategic Doctor Partnerships: Building long-term alignment through equity participation, fostering ownership, retention, and clinical excellence. Regional Market Leadership Strategy: Focused expansion to establish dominant presence in target geographies and accelerate new business growth. Demonstrated Investor Value Creation: Delivered consistent stock performance since listing, reflecting strong fundamentals and strategic growth. Sustained Performance Driving for Long Term Growth These Strategic levers underpin the next phase of expansion Adding 700+ Beds through Green Field, Acquisitions & O&M Opportunities
Page 15
15 Private & Confidential Q2 FY27 Updates
Page 16
16 Private & Confidential Financial & Operational Highlights - 1/2 Particulars Financial Highlights Q2 FY27 Q1 FY27 Q2 FY26 QoQ (%) YoY (%) H1 FY27 H1 FY26 YoY (%) Operating Revenue 13,444 11,795 9,607 14.0% 39.9% 25,239 18,323 37.7% Other Income 186 164 42 13.4% 342.9% 350 113 209.7% Total Revenue 13,630 11,959 9,649 14.0% 41.3% 25,589 18,436 38.8% EBITDA 2,789 2,398 2,082 16.3% 34.0% 5,187 4,079 27.2% EBITDA (%) on Total Revenue 20.5% 20.1% 21.6% 20.3% 22.1% PBT* 1,066 566 968 88.3% 10.1% 1,632 2,105 (22.5%) PBT (%) on Total Revenue 7.8% 4.7% 10.0% 6.4% 11.4% PAT* 757 374 720 102.4% 5.1% 1,131 1,570 (28.0%) PAT (%) on Total Revenue 5.6% 3.1% 7.5% 4.4% 8.5% Basic EPS(Rs.) 1.81 1.04 1.67 74.2% 8.5% 2.86 3.64 (21.4%) Diluted EPS (Rs.) 1.81 1.04 1.67 74.2% 8.5% 2.86 3.64 (21.4%) IND AS 116 287 177 75 464 134 EBITDA Pre IND AS 2,502 2,221 2,007 12.6% 24.6% 4,723 3,945 19.7% (Rupees in Millions) *PBT and PAT include (Loss)/gain on fair valuation of Call option (net) (3) Mn In Q2 FY26 & 132 Mn In Q2 FY27. *PBT and PAT include Share of profit from associate net of tax 10 Mn in Q1 FY27 & 7 Mn in Q2 FY27.
Page 17
17 Private & Confidential Financial & Operational Highlights - 2/2 Particulars Operational Highlights Q2 FY27 Q1 FY27 Q2 FY26 QoQ (%) YoY (%) H1 FY27 H1 FY26 YoY (%) IP Volume 81,668 72,493 64,288 12.7% 27.0% 1,54,161 1,21,563 26.8% OP Volume 7,31,010 6,58,617 5,92,725 11.0% 23.3% 13,89,627 11,05,124 25.7% ARPOB (Rs) 48,277 47,200 42,016 2.3% 14.9% 47,768 42,483 12.4% ARPP (Rs) 1,65,577 1,63,573 1,50,624 1.2% 9.9% 1,64,635 1,51,788 8.5%
Page 18
18 Private & Confidential Group Operating Performance IP VOLUME (‘000) OCCUPIED BEDS / OCCUPANCY %* 55.0% 2,510 Q2 FY26 50.2% 2,761 54.3% 3,045 Q1 FY27 Q2 FY27 52.5% 2,394 H1 FY26 51.8% 2,903 H1 FY27 122 H1 FY26 154 H1 FY27 26.8% 64 Q2 FY26 72 82 Q1 FY27 Q2 FY27 *Occupancy (Occupied Beds/Operational Beds). 12.7% ARPOB (‘000) 2.3% 42.0 Q2 FY26 47.2 48.3 Q1 FY27 Q2 FY27 42.5 H1 FY26 47.8 H1 FY27 12.4% OP VOLUME (‘000) 1,105 H1 FY26 1,390 H1 FY27 25.7% 593 Q2 FY26 659 731 Q1 FY27 Q2 FY27 11.0%
Page 19
19 Private & Confidential Particulars FY 26 H1 FY27 H1 FY26 Q2 FY26 Q1 FY27 Q2 FY27 Bed Capacity# 6,464 7,459 6,114 6,114 7,459 7,459 Operational Beds 4,717 5,605 4,560 4,560 5,504 5,605 Census Beds 3,845 4,508 3,747 3,747 4,413 4,508 Non Census Beds 872 1,097 813 813 1,091 1,097 Occupied Beds 2,450 2,903 2,394 2,510 2,761 3,045 Occupancy** 51.9% 51.8% 52.5% 55.0% 50.2% 54.3% IP volume 2,46,297 1,54,161 1,21,563 64,288 72,493 81,668 OP volume 23,00,360 13,89,627 11,05,124 5,92,725 6,58,617 7,31,010 ARPOB(Rs.) 44,644 47,768 42,483 42,016 47,200 48,277 ARPP(Rs.) 1,59,575 1,64,635 1,51,788 1,50,624 1,63,573 1,65,577 ALOS 3.57 3.45 3.57 3.58 3.47 3.43 Total Revenue (Rs.in Mn) 39,308 25,589 18,436 9,649 11,959 13,630 EBITDA (Rs.in Mn) 8,282 5,187 4,079 2,082 2,398 2,789 EBITDA % to Total Revenue 21.1% 20.3% 22.1% 21.6% 20.1% 20.5% PBT* (Rs. in Mn) 3,339 1,632 2,105 968 566 1,066 PAT* (Rs. in Mn) 2,420 1,131 1,570 720 374 757 Group Operating and Financial Performance *PBT and PAT include (Loss)/gain on fair valuation of Call option (net) (3) Mn In Q2 FY26 & 132 Mn In Q2 FY27. *PBT and PAT include Share of profit from associate net of tax 10 Mn in Q1 FY27 & 7 Mn in Q2 FY27. **Occupancy (Occupied Beds/Operational Beds). #Secunderabad Unit has a total bed capacity of 1,000 beds, of which 750 beds are currently operational and 250 beds are under construction.
Page 20
20 Private & Confidential Group Financial Performance (Rupees in Millions) TOTAL REVENUE PBT* 18,436 H1 FY26 25,589 H1 FY27 38.8% 9,649 11,959 13,630 14.0% Q2 FY26 Q1 FY27 Q2 FY27 2,105 H1 FY26 1,632 H1 FY27 968 566 1,066 88.3% Q2 FY26 Q1 FY27 Q2 FY27 (22.5%) EBITDA PAT* 4,079 H1 FY26 5,187 H1 FY27 27.2% 2,082 2,398 2,789 16.3% Q2 FY26 Q1 FY27 Q2 FY27 1,570 H1 FY26 1,131 H1 FY27 (28.0%) 720 374 757 102.4% Q2 FY26 Q1 FY27 Q2 FY27 *PBT and PAT include (Loss)/gain on fair valuation of Call option (net) (3) Mn In Q2 FY26 & 132 Mn In Q2 FY27. *PBT and PAT include Share of profit from associate net of tax 10 Mn in Q1 FY27 & 7 Mn in Q2 FY27.
Page 21
21 Private & Confidential 1) Intercompany eliminations adjusted in Telangana. 2) Telangana - Secunderabad, Kondapur, Gachibowli, Begumpet, MIPPL and Asian Transcare. 3) Andhra Pradesh - Nellore, Rajahmundry, Srikakulam, Ongole, Vizag (Sheela Nagar & Seethammadhara), Anantapur and Kurnool. 4) *Occupancy (Occupied Beds/Operational Beds). 5) #Secunderabad Unit has a total bed capacity of 1,000 beds, of which 750 beds are currently operational and 250 beds are under construction. Particulars Telangana Andhra Pradesh FY26 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 FY26 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 Bed Capacity# 1,882 1,882 2,669 1,882 2,669 2,669 2,314 2,314 2,314 2,314 2,314 2,314 Operational Beds 1,559 1,559 2,009 1,559 2,009 2,009 1,840 1,813 1,952 1,813 1,909 1,952 Census Beds 1,264 1,264 1,586 1,264 1,586 1,586 1,634 1,626 1,731 1,626 1,694 1,731 Non Census Beds 295 295 423 295 423 423 206 187 221 187 215 221 Occupied Beds 889 898 940 952 881 999 1,009 1,044 1,163 1,064 1,133 1,193 Occupancy* 57.0% 57.6% 46.8% 61.1% 43.9% 49.7% 54.8% 57.6% 59.6% 58.7% 59.4% 61.1% IP volume 93,038 47,395 52,599 24,519 24,327 28,272 1,01,575 52,617 58,948 27,328 28,536 30,412 OP volume 9,42,195 4,72,839 5,08,087 2,42,581 2,42,274 2,65,813 7,84,509 3,96,318 4,22,536 2,12,782 2,06,906 2,15,630 ARPOB(Rs.) 69,450 67,465 76,327 65,396 77,009 75,731 25,595 24,300 25,791 24,519 25,448 26,113 ARPP(Rs.) 2,42,340 2,34,023 2,49,680 2,33,611 2,53,856 2,46,086 92,766 88,200 93,114 87,852 91,940 94,215 ALOS 3.49 3.47 3.27 3.57 3.30 3.25 3.62 3.63 3.61 3.58 3.61 3.61 Total Revenue (Rs.in Mn) 22,420 11,014 13,253 5,647 6,235 7,019 9,496 4,677 5,517 2,430 2,634 2,882 EBITDA (Rs.in Mn) 6,820 3,338 3,734 1,752 1,842 1,892 2,337 1,171 1,116 672 560 556 EBITDA % to Total Revenue 30.4% 30.3% 28.2% 31.0% 29.5% 27.0% 24.6% 25.0% 20.2% 27.7% 21.3% 19.3% Operational and Financial Performance - 1/3
Page 22
22 Private & Confidential 1) Maharashtra - Nagpur, Nashik & Thane. 2) Keralam - Kannur, Kollam & Palakkad. 3) *Occupancy (Occupied Beds/Operational Beds). Particulars Maharashtra Keralam FY26 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 FY26 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 Bed Capacity 959 959 959 959 959 959 509 509 717 509 717 717 Operational Beds 637 637 695 637 637 695 401 401 609 401 609 609 Census Beds 442 442 500 442 442 500 321 321 481 321 481 481 Non Census Beds 195 195 195 195 195 195 80 80 128 80 128 128 Occupied Beds 332 293 404 314 373 435 160 148 287 169 280 293 Occupancy* 52.1% 46.0% 58.1% 49.3% 58.6% 62.6% 39.9% 36.9% 47.1% 42.1% 46.0% 48.1% IP volume 29,393 13,060 19,267 7,552 8,731 10,536 18,443 8,331 16,276 4,729 7,851 8,425 OP volume 2,98,296 1,30,472 1,45,344 78,390 68,632 76,712 2,21,405 1,02,992 2,06,091 56,469 96,934 1,09,157 ARPOB(Rs.) 39,402 37,753 44,405 38,323 44,182 44,595 29,063 27,880 30,302 27,027 30,125 30,470 ARPP(Rs.) 1,57,484 1,48,223 1,70,445 1,46,759 1,71,610 1,69,479 91,776 90,852 97,642 88,708 97,781 97,513 ALOS 4.00 3.93 3.84 3.83 3.88 3.80 3.16 3.26 3.22 3.28 3.25 3.20 Total Revenue (Rs.in Mn) 4,654 1,949 3,294 1,118 1,504 1,790 1,713 765 1,609 425 776 833 EBITDA (Rs.in Mn) (43) (161) 403 (96) 113 290 78 (17) 180 7 75 105 EBITDA % to Total Revenue (0.9%) (8.3%) 12.2% (8.6%) 7.5% 16.2% 4.6% (2.2%) 11.2% 1.6% 9.7% 12.6% Operational and Financial Performance - 2/3
Page 23
23 Private & Confidential Particulars Karnataka Group FY26 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 FY26 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 Bed Capacity# 800 450 800 450 800 800 6,464 6,114 7,459 6,114 7,459 7,459 Operational Beds 280 150 340 150 340 340 4,717 4,560 5,605 4,560 5,504 5,605 Census Beds 184 94 210 94 210 210 3,845 3,747 4,508 3,747 4,413 4,508 Non Census Beds 96 56 130 56 130 130 872 813 1,097 813 1,091 1,097 Occupied Beds 61 10 110 10 94 125 2,450 2,394 2,903 2,510 2,761 3,045 Occupancy* 21.8% 6.7% 32.4% 6.7% 27.6% 36.8% 51.9% 52.5% 51.8% 55.0% 50.2% 54.3% IP volume 3,848 160 7,071 160 3,048 4,023 2,46,297 1,21,563 1,54,161 64,288 72,493 81,668 OP volume 53,955 2,503 1,07,569 2,503 43,871 63,698 23,00,360 11,05,124 13,89,627 5,92,725 6,58,617 7,31,010 ARPOB(Rs.) 85,320 51,640 94,050 51,640 92,793 94,983 44,644 42,483 47,768 42,016 47,200 48,277 ARPP(Rs.) 2,62,952 1,67,480 2,66,621 1,67,480 2,60,082 2,71,576 1,59,575 1,51,788 1,64,635 1,50,624 1,63,573 1,65,577 ALOS 3.08 3.24 2.83 3.24 2.80 2.86 3.57 3.57 3.45 3.58 3.47 3.43 Total Revenue (Rs.in Mn) 1,025 31 1,916 29 810 1,106 39,308 18,436 25,589 9,649 11,959 13,630 EBITDA (Rs.in Mn) (910) (252) (246) (253) (192) (54) 8,282 4,079 5,187 2,082 2,398 2,789 EBITDA % to Total Revenue (88.8%) (812.9%) (12.8%) (872.4%) (23.7%) (4.9%) 21.1% 22.1% 20.3% 21.6% 20.1% 20.5% Operational and Financial Performance - 3/3 1) Karnataka - Bengaluru (Mahadevapura and Electronic City). 2) *Occupancy (Occupied Beds/Operational Beds). 3) #Secunderabad Unit has a total bed capacity of 1,000 beds, of which 750 beds are currently operational and 250 beds are under construction.
Page 24
24 Private & Confidential Ramp-up of Keralam Units (Rupees in Millions) Revenue EBITDA • Secured the first-ever Liver Transplant License in the North Malabar region. • Successfully executed a complex Swap Renal Transplant. Kannur 353.6 52.7 Q1FY27 272.4 28.0 Q2FY26 347.0 56.1 Q2FY27 EBITDA Positive NABH - In Pipeline • Successfully deployed Linear EBUS-TBNA for real-time ultrasound visualization and needle aspiration. • Integrated Rapid On-Site Evaluation (ROSE) for live microscopic sample validation. • Successfully performed the region's first Thoracoscopy procedure, highlighting our hospital’s leadership in introducing advanced minimally invasive surgical techniques. Kollam 219.3 152.2 14.8 (21.1) Q1FY27Q2FY26 227.1 18.5 Q2FY27 NABH - In Pipeline EBITDA Positive • Successfully implanted a highly advanced Leadless Pacemaker. • Successfully completed our first Renal Transplant. Palakkad 203.1 7.0 Q1FY27 259.4 30.6 Q2FY27 NABH - Accredited EBITDA Positive
Page 25
25 Private & Confidential Ramp-up of Maharashtra Units (Rupees in Millions) • Successfully performed North Maharashtra's first swap kidney transplant. • Successfully managed the first ECMO (Extracorporeal Membrane Oxygenation) case in North Maharashtra. • Launched the Fat to Fit Metabolic Clinic, positioned as the first of its kind in North Maharashtra. • Launched Neuro Equilibrium services, becoming the second centre in North Maharashtra. • Successfully launched with completion of a live robotic and cadaveric kidney transplant, including the first international ABO-incompatible robotic kidney transplant. • Received Best ESG Initiative Award at the CII Innovation Awards, CII Hospital Tech 2026. Revenue EBITDA Nashik 248.8 10.8 Q1FY27 268.4 21.9 Q2FY27 176.4 (64.7) Q2FY26 NABH - In Pipeline Thane 482.0 (79.9) Q1FY27 645.4 29.7 Q2FY27 298.1 (150.0) Q2FY26 NABH - Accredited EBITDA Positive EBITDA Positive
Page 26
26 Private & Confidential Ramp-up of AP & Karnataka Units (Rupees in Millions) Revenue EBITDA • NABH & NABL accreditation audit successfully completed at Electronic City. • 50+ organ transplants performed. • 110+ robotic surgeries completed, including advanced orthopaedic cases. Electronic City (Bengaluru) 259.0 (176.6) Q1FY27 410.3 (106.0) Q2FY27 NABH - Accredited Vizag Seethammadhara 238.9 14.6 Q2FY26 398.8 63.2 Q1FY27 494.1 60.7 Q2FY27 NABH - Accredited EBITDA Positive • Secured Liver & Kidney Transplant Licenses, strengthening advanced tertiary care capabilities. • Successfully performed the unit’s first Kidney and Liver Transplants. • Enhanced clinical offerings with the introduction of EP Cardiology, Physiotherapy, and Rehabilitation Services. Mahadevapura (Bengaluru) 29.0 (182.8) Q2FY26 550.6 (15.8) Q1FY27 NABH - Accredited 696.0 52.1 Q2FY27 EBITDA Positive
Page 27
27 Private & Confidential Ramp-up of O&M Units (Rupees in Millions) Revenue EBITDA Revenue and EBITDA are as per management accounts. • Empaneled key insurance partners, enhancing patient accessibility and ensuring continuity of care. • Successfully performed a Cadaveric Kidney Transplant. Sangli 247.6 14.2 Q2FY26 277.4 22.6 Q1FY27 284.8 24.7 Q2FY27 EBITDA Positive NABH - In Pipeline • 1,316 Surgeries performed across specialties. • 13 High-Risk Complex Procedures successfully executed across Cardiology, Pulmonology, Paediatric CTVS, Neurosurgery, and Plastic Surgery. • 7+ Liver & Kidney Transplants completed. Guntur 230.8 (30.9) Q2FY26 317.9 18.7 Q1FY27 NABH - In Pipeline 351.4 26.6 Q2FY27 EBITDA Positive • 900+ Surgeries performed across all specialties. • Launched Oncology services, expanding the clinical portfolio. Kompally NABH - In Pipeline 121.4 (92.1) Q1FY27 226.4 (22.7) Q2FY27
Page 28
28 Private & Confidential Revenue Mix & Cluster Profile (Group H1FY27) 1) Telangana - Secunderabad, Kondapur, Begumpet, Gachibowli, Asian Transcare & MIPPL. 2) Andhra Pradesh - Nellore, Rajahmundry, Srikakulam, Ongole, Vizag (Sheela Nagar & Seethammadhara), Anantapur & Kurnool. 3) Maharashtra - Nagpur, Nashik & Thane. 4) Keralam - Kannur, Kollam & Palakkad. 5) Karnataka - Bengaluru (Mahadevapura & Electronic City). PAYOR MIX Cash 53% Aarogyasri 4% Insurance 32% Corporate 11% CLUSTER EBITDA Andhra Pradesh 21.4% Telangana 72.0% Maharashtra 7.8%Keralam 3.5% Karnataka (4.7%) CLUSTER TOTAL REVENUE Andhra Pradesh 21.5% Telangana 51.8% Maharashtra 12.9% Karnataka 7.5% Keralam 6.3% Oncology 8% Neuro Sciences 10% Orthopaedics 14% Gastric Sciences 9% Organ Transplant 3% Mother & Child 9% Cardiac Sciences 14% Renal Sciences 9% Others 24% SPECIALITY MIX
Page 29
29 Private & Confidential Key Achievements in Q2 FY27
Page 30
30 Private & Confidential Key Achievements in Q2 FY27
Page 31
31 Private & Confidential Corporate Structure (As on 30th September 2026) Krishna Institute of Medical Sciences Limited KIMS Secunderabad (100%) KIMS Nellore (100%) KIMS Seethammadhara Visakhapatnam (100%) KIMS Rajahmundry (100%) KIMS Swastha Keralam (100%) KHPL Rajahmundry (100%) KIMS Ongole (100%) Doctor Partnership Hospitals AHPL Srikakulam (65.9%) KHEPL Kondapur (91.1%) KIMS ICON Visakhapatnam (51.0%) KIMS Saveera Anantapur (76.1%) KIMS Kurnool (55.0%) KIMS Sunshine Begumpet & Gachibowli (77.8%) MIPPL (Meda) Hyderabad (51.0%) KIMS-Manavata Nashik (51.0%) SPANV Nagpur (69.3%) KIMS Hospitals Bengaluru (79.9%) KIMS Thane (100%) Units Wholly Owned Subsidiaries
Page 32
32 Private & Confidential Thank You